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Abstract: The effects of formulation characteristics on acceptability are poorly understood. This
study evaluated the validity and feasibility of using the Medication Acceptability Questionnaire
(MAQ) to investigate factors influencing acceptability of tablet compared with liquid alendronic acid.
Written consent was obtained from eligible patients on Older People’s Medicine wards. MAQ face
and content validity were evaluated through cognitive interviews while internal consistency and
criterion validity were investigated by calculating Cronbach’s alpha and correlation of MAQ items
with visual analogue scale (VAS) responses. MAQ data were obtained from 33 and 25 participants for
tablet and liquid formulations respectively. Cognitive interviews indicated MAQ face and content
validity. The domains of appearance, efficacy, and tolerability demonstrated adequate internal
consistency and suitable refinements were identified for the domains of convenience and taste with
Cronbach’s alpha <0.7. Significant positive correlations were identified between all MAQ domains
and VAS. The liquid trended towards performing better for taste, appearance and tolerability and the
tablet for convenience and efficacy. It is feasible to capture patient acceptability of a medication by
questionnaire. Interpatient variation in acceptability for two formulations indicates that medication
characteristics should be considered during prescribing and medication reviews to match patient
preference with the appropriate formulation.
Keywords: medication adherence; bisphosphonate; preference; side effect; alendronate
1. Introduction
Over 40% of UK women aged over 70 years have osteoporosis [1] for which oral, once weekly
bisphosphonate therapy with alendronic acid 70 mg tablet is standard UK prescribing practice.
Unfortunately, 50% of patients at a high risk of a fracture discontinue their bisphosphonate within four
weeks of starting [2–4]. This non-adherence increases fracture risk and avoidable healthcare costs [4,5].
Non-adherence is often an amalgam of intentional and unintentional factors. Unintentional
non-adherence arises from factors beyond the patient’s control such as confusion, forgetfulness
and physical impairments [6]. There is a consistent causal relationship between dysphagia and
unintentional non-adherence [7,8]. The incidence of dysphagia increases with age, ranging from 15%
for independently living older people to 68% for the institutionalized [9,10]. Consequently, a significant
proportion of people with osteoporosis who are prescribed tablets may find them difficult to swallow.
The liquid formulation of the bisphosphonate alendronic acid, may provide a suitable alternative
to such patients and therefore reduce the likelihood of unintentional non-adherence.
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Intentional non-adherence arises when the prescribed medication is not acceptable to the patient.
Once daily dosing is generally more acceptable and associated with increased adherence relative to
multiple dosing regimens [11,12]. However, there are reports of alendronic acid treatment cessation
initiated by the patient due to experiences of gastro intestinal side effects and the word ‘acid’ in
the medication’s name causing concern [3]. There is substantial research investigating how these
factors influence adherence but little information regarding other medication related factors such as
formulation characteristics.
The availability of a liquid formulation of alendronic acid may address some of the unintentional
and intentional factors associated with bisphosphonate therapy non-adherence. An observational
retrospective study (n = 375) comparing different bisphosphonates including liquid alendronic acid
reported significantly greater persistence with the liquid relative to weekly, monthly, and bimonthly
formulations of bisphosphonates. As the study compared different bisphosphonates, the effect of
formulation alone could not be isolated [13].
The Medication Adherence Report Scale (MARS®) is a validated tool for measuring self-reported
adherence. MARS® comprises the five medication non-adherence behaviors of forgetting, altering
dose, stopping, missing a dose, and taking less. Each of these behaviors is rated on a five-point Likert
scale ranging from always to never [14]. No such validated tool is available for measuring acceptability
to medication.
The Medication Acceptability Questionnaire (MAQ) is a newly developed tool to measure patient
acceptability to medication formulations [15]. The MAQ is derived from a systematic review of
formulation characteristics influencing medication acceptability [16]. This methodological approach to
MAQ development affords some confidence in content validity [17]; however further investigation of
its psychometric properties is required. MAQ comprises 20 items grouped under the five key domains
of medication acceptability identified from the systematic review [16]: convenience (5 items); taste
(4 items); appearance (6 items); efficacy (3 items); tolerability (2 items). Each of the items is rated by
the respondent on a five-point Likert scale ranging from strongly agree to strongly disagree. Global
acceptability with respect to each of the five domains is captured on a 10-point visual analogue scale
(VAS). An indication of global formulation acceptability is provided by a final 10-point VAS. The
MAQ is available at the following website: http://www.uea.ac.uk/pharmacy/research/maq and is
provided in Supplementary File S1.
The present study aims to investigate the psychometric properties of the MAQ and feasibility
of using the tool within a trial environment. The study also aims to explore any trends between
alendronic acid formulation and, patient acceptability and adherence. The sample size required should
a future definitive trial be appropriate will also be estimated.
2. Materials and Methods
2.1. Ethics Approval
Ethical and research governance approval were obtained from the London Bromley ethics
committee and Norfolk and Norwich University Hospital respectively.
2.2. Questionnaire Testing and Refinement
Face and content validity of the Medication Acceptability Questionnaire (MAQ) were assessed
through cognitive interviews with patients of Older People’s Medicine wards prescribed tablet
alendronic acid. Cognitive interviewing is a form of verbal reporting that allows evaluation of how
the target audience perceives survey instruments and their constructs. How a participant interprets a
question, processes the information, applies information stored in memory and prepares a response
are captured as verbal data during the cognitive interview process. Data gathered may be used to
identify survey flaws and improve questions prior to administration in a study [18,19].
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Participants in the presence of a research nurse, were asked to concurrently verbalize their thought
processes as they completed the MAQ and the research nurse documented any difficulties encountered
with understanding, processing, or responding to questions. After completing the MAQ, the research
nurse further explored identified difficulties through verbal probing. Where appropriate, participants
were asked to suggest improvements to elements of the MAQ that presented difficulties.
Cognitive interviews were continued until no further adaptations were necessary. Participants
were also asked whether any factors influencing medication acceptability were unrepresented in the
MAQ. The MAQ was iteratively refined to enhance interpretation and ease of response, indicating face
and content validity [19].
2.3. Study Sample and Setting
2.3.1. Eligibility
Inpatients from an Older People’s Medicine ward regularly prescribed once weekly alendronic
acid tablet were eligible for recruitment into the study with the following exclusions:
• Deemed by the healthcare team as unable to provide written, informed consent
• Unable to self-administer medication during in-patient stay or unlikely to self-administer
post discharge
• Dysphagia (Functional Oral Intake Scale score <7) [20]
2.3.2. Sample Size
As a feasibility study, neither sample size estimation nor statistical comparisons between the
tablet and liquid formulation were undertaken. Sample sizes of between 24 and 50 participants have
been recommend for feasibility studies [21,22]. Accordingly, the present study aimed to recruit to
within this range.
Dispensing data at the hospital research site suggest a minimum of 20 Older People’s Medicine
ward patients per month will be prescribed tablet alendronic acid. Based on a conservative estimate of
30% patient eligibility for study participation and consent, over a 6-month recruitment period, data for
36 participants will be available for analysis.
2.4. Recruitment and MAQ Administration
Patients were screened for eligibility and approached for inclusion by a research nurse. Written,
informed consent was obtained prior to study enrolment. Participant demographic characteristics plus
the following were recorded:
• History of swallowing difficulties
• Manual dexterity assessed by observing participant’s ability to a bottle of liquid alendronic acid
and the Hand Grip Strength Test [23]
• Cognitive function assessed by the Abbreviated Mental Test Score [24]
Tablet acceptability and self-reported adherence were captured by participants completing the
MAQ and the MARS® [14] respectively based on their existing experiences of taking tablet alendronic
acid. A four-week supply of the licensed once weekly liquid alendronic acid was then provided instead
of the tablet. This was dispensed as four 100 mL bottles each providing the once weekly dosage of
70 mg alendronic acid. A target of 14 days post liquid initiation was set for re-contacting participants
to collect liquid MAQ and MARS® data. The actual date of re-contact was recorded to capture any
variation in duration of liquid use. Additionally, for the liquid formulation, medication possession ratio
was calculated by inviting patients to report the remaining quantity of liquid alendronic acid bottles.
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2.5. Statistical Analysis and Psychometric Testing
Descriptive statistics were calculated for swallowing, manual dexterity, and cognitive function.
Each item of the MAQ was scored from 1 indicating ‘strongly disagree’ through to 5 indicating ‘strongly
agree’. For each of the five MAQ domains, the item scores were summed giving a domain score. For
the domain of tolerability, the items were negatively phrased thus data were inverted for comparison.
Domain scores were reported as percentages of the total possible score to adjust for domains having
different numbers of items. The domain VAS score ranging from 0 indicating very low acceptability to
10 for maximum acceptability was reported for each of the five domains. Mean and 95% confidence
intervals [95% CI] or median and interquartiles (IQ) were reported as appropriate to describe VAS
global acceptability of the tablet and liquid formulations. MARS® data were handled similarly; MARS®
scores range from 5 to 25 and any deviation from 25 was classified as non-adherence [14].
Regression analysis was performed to identify which of the MAQ domains predict global
formulation acceptability. This was based on a two-stage approach. Firstly, the correlation between
each domain and acceptability was calculated and then a multiple linear regression model including
all significant domains was estimated. This enabled identification of the subdomains independently
associated with acceptability. If the residuals were not normally distributed, then the non-parametric
bootstrap was used.
Tablet and liquid formulation data were combined to investigate MAQ psychometric properties.
Internal consistency of items within each of the five domains was assessed using Cronbach’s alpha, with
α ≥ 0.7 deemed acceptable [25]. Spearman’s or Pearson’s correlations were performed to investigate
domains with poor internal consistency to identify the items performing poorly and thus requiring
adaptation or removal.
Criterion validity was investigated by exploring the relationships between domain subscale scores
and their corresponding VAS using Spearman’s and Pearson’s correlation coefficients as appropriate.
Any weak or inverse relationships identified between the subscale scores and VAS would suggest that
one or more of the items are not capturing the intended attitudes towards the medication.
An estimate of the sample size necessary for a study powered to identify difference in acceptability
between a tablet and liquid formulation of alendronic acid was also calculated.
3. Results
3.1. Questionnaire Testing and Refinement
After three cognitive interviews with patients, no recommendations for improving understanding
of the MAQ statements were identified as all reported that the MAQ was easy to answer. All three
participants reported that it was helpful in making them think about the characteristics of their
medication; they used the terms “very informative”, “makes you wonder why” and “a good and
helpful thing”.
No additional factors potentially influencing acceptability not already present in the MAQ were
proposed. As face and content validity were demonstrated, no changes were made to the MAQ and no
further interviews convened. Cognitive interview participants were female and aged 77 to 85 years.
None reported any swallowing difficulties, nor did any have cognitive impairment, one participant
reported difficulty with opening sealed boxes.
3.2. Recruitment
Figure 1 summarizes participant flow throughout the study. Of the 742 patients screened for
inclusion, 35 (5.27% ± 1.67) were recruited. The primary reasons for exclusion were not able to
self-administer medication, impaired cognitive function and the patient being discharged before
they could be approached. A total of 35 patients consented and provided demographic information;
however, 2 (5.7%) participants withdrew before completing the tablet questionnaire. Of the remaining
33 participants who completed the tablet questionnaire, eight (24.2%) withdrew from the study before
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completing the liquid questionnaire. Data for 25 liquid questionnaires were returned, which was
within the target sample size range; however, four (16.0%) were incomplete.
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Figure 1. Participant recruitment flow chart.
The median (IQ) age for the 33 participants who provided tablet questionnaire data was 84.0
years (78.5, 88.0), of which 28 (84.8%) were female. Participants were prescribed a median (IQ) of 9 (6.0,
11.0) medicines. Abbreviated Mental Test Scores were available for 32 participants and the median (IQ)
score was 10 (9, 10), indicating no cognitive impairment [26]. The median (IQ) dominant hand grip
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test result for males was 14.0 kg (11.0, 18.0) [normative mean = 33 kg] and 10 kg (5.3, 14.0) [normative
mean = 20] for females [23]. A history of difficulty with swallowing tablets or accessing them from
packaging was reported by 3 (9.1%) of the 31 participants who provided information. The median (IQ)
duration between administration of the MAQ for the tablet and liquid formulations of alendronic acid
was 14 (12.5, 20.0) days. As the liquid alendronic acid supply was provided immediately after MAQ
administration for tablet acceptability, the median (IQ) duration of liquid alendronic acid treatment
was also 14 (12.5, 20.0) days.
3.3. Questionnaire Responses and Psychometric Testing
Table 1 provides the Cronbach’s alpha values for each of the five MAQ domains. The items of
most domains perform well except taste. Further investigation of the relationships between the three
item scores for taste and the VAS score for taste, indicates that the item ‘the medicine has no aftertaste’
only has a weak positive Spearman’s correlation coefficient with the other two items in this domain:
‘the medicine tastes good’ and ‘the medicine has a good texture’ (R = 0.267 and 0.31 respectively). Both
correlations are significant at p < 0.05. The domain of convenience is also slightly below the accepted α
threshold of 0.7. The item “is suitable to take when not at home” had a non-significant Spearman’s
correlation coefficient with the items “has a convenient dose frequency” and “is a convenient amount
for me to take” (R = 0.1 and 0.2 respectively).
Table 1. Relationships between MAQ domain items and, domain subscale scores with their
corresponding visual analogue scale (VAS).
MAQ Domain Internal Consistency(α) between Domain Item Scores
Criterion Validity
Spearman’s Correlation
Coefficient (p-Value) between
Domain Subscale Score and
Corresponding VAS
Convenience 0.65 0.63 (<0.001)
Taste 0.56 0.65 (<0.001)
Appearance 0.71 0.58 (<0.001)
Efficacy 0.81 0.71 (<0.001)
Tolerability 0.91 0.37 (0.005)
Table 1 also summarizes the relationship between the domain subscale scores and the
corresponding domain VAS. A strong positive correlation was present in all cases except for the
tolerability domain. Spearman’s correlations for the two items in the tolerability domain indicate
that both statements only have weak negative correlations with the VAS score for the domain: ‘the
medicine makes me feel ill all of the time’ (R = −0.28, p < 0.05) and ‘the medicine makes me feel ill for
a short time just after taking it’ (R = −0.40, p < 0.01).
Figure 2 illustrates participant responses to the five subscale scores. The median scores for both
the tablet and liquid were relatively similar. The MAQ demonstrated ability to discriminate between
the two formulations as based on the interquartiles; there was a general trend for the liquid to perform
better in terms of taste, appearance, and tolerability and for the tablet to perform better in terms of
convenience and perceived efficacy. The statement within the subscale domain of convenience that
elicited the greatest difference between tablet and liquid was ‘It is suitable to take when not at home’.
The median (IQ) score for the tablet was 4.0 (4.0, 4.0) indicating that at least 75% of participants agreed
with the statement. However, the liquid scored 4.0 (2.0, 4.0) indicating that only 50% of the participants
agreed with this statement.
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MAQ lso discriminated between the different subscales as the efficacy and tolerability subscales
had scores at around 60% for both formulations while the remaining three subscale domains ll had
median values above 70%.
The median (IQ) global acceptability score for the tablet was marginally higher than the liquid
with 9 (7.5, 10.0) compared to 8 (5.0, 10.0).
Spearman and Pearson correlations between each of the five subscale domain scores and global
acceptability are summarized in Table 2. For the tablet, only the subscale domains of convenience and
taste demon trated a significant positive correlation with global acceptability. For the liquid all the
subscale domain scores demonstrated a positive correlation with global acceptability and in all cases,
except for tolerability, these were significant relationships.
Table 2. Spearman’s correlations between domain subscale scores and global acceptability visual
analogue scale (VAS).
Subscale Domain
Correlation Coefficient (p-Value)
Tablet Global Acceptability VAS Liquid Global Acc ptability VAS
Convenience 0.40 (0.022) 0.63 (0.001)
Taste 0.41 (0.018) 0.64 (0.001)
*Appearance −0.17 (0.355) 0.44 (0.031)
Efficacy 0.21 (0.243) 0.62 (0.002)
*Tolerability inverted −0.06 (0.753) 0.20 (0.361)
* Pearson’s correlation.
Informed by the statistically significant correlations reported in Table 2, convenience, taste,
appearance, and efficacy were entered into a multiple regression analysis; the models are provided
in Table 3. The resulting model predicted 56.4% of the variance (R2 = 0.564, p = 0.001) of tablet
global acceptability. The overall VAS score for taste and appearance made a statistically significant
contribution to the prediction. A higher taste score predicted a higher global acceptability score
(B = 1.212, p < 0.001), after adjustment, a lower appearance score was predictive of higher tablet global
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acceptability (B = −0.678, p < 0.001). The model for predicting global acceptability score for the liquid
accounted for approximately 67% of the variance (R2 = 0.668, p < 0.05). The sub scale domains that were
statistically significant to the prediction were convenience (B = 0.495, p < 0.05) and taste (B = 0.629,
p < 0.05). With both domains, the higher score predicted a higher global acceptability VAS score.
Table 3. Multiple regression models for the tablet and liquid formulations of alendronic acid identifying
which of the MAQ domains predict global formulation acceptability.
Tablet Global Acceptability VAS Liquid Global Acceptability VAS
Subscale Domain RegressionCoefficient (95% CI) p-Value
Regression
Coefficient (95% CI) p-Value
Convenience −0.09 (−0.53, 0.34) 0.675 0.50 (0.05, 0.94) 0.032
Taste 1.21 (0.57, 1.86) <0.001 0.63 (0.13, 1.13) 0.017
Appearance −0.68 (−1.05, −0.3) <0.001 −0.05 (−0.56, 0.46) 0.837
Efficacy 0.30 (−0.04, 0.63) 0.077 0.53 (−0.25, 1.30) 0.167
Tolerability inverted −0.01 (−0.28, 0.26) 0.938 −0.11 (−0.92, 0.70) 0.769
Constant 10.74 (3.94, 17.54) 0.002 −12.77 (−26.66, 1.12) 0.069
MARS® median (IQ) score (n = 24) for the liquid was slightly higher at 25.0 (24.0, 25.0) compared
with 24.0 (24.0, 25.0) for the tablet [14]. Liquid alendronic acid usage data were available for 21 of the
25 participants and all had used enough bottles indicating 100% persistence. If treatment cessation is
assumed for the four participants for whom data were unavailable, the most conservative estimate of
persistence with liquid treatment was 84%.
The most appropriate primary outcome measure for a future definitive study is tolerability as
there is potential for direct clinical benefit if the liquid is better tolerated. The mean (SD) tolerability
subscale score for the tablet was 6.21 (1.92) compared with 6.54 (1.35) for the liquid. A difference in
subscale score between the two formulations of 0.5 was considered clinically important. The pooled
standard deviation across both the tablet and liquid group was 1.6. Assuming a SD of 1.6, to detect a
difference of 0.5 in subscale score between the two formulations with 80% power, a sample size of 161
per group and thus a total sample of 322 participants will be required for a definitive parallel group
randomized controlled trial.
4. Discussion
The high rate of MAQ completion indicates that it is an acceptable tool for use in a trial
environment with an older population. The observed variations in acceptability of the tablet and liquid
formulation indicate that the MAQ can discriminate between formulations; further work is required to
determine whether these results are stable over time through undertaking test-retest reliability analysis.
From a clinical perspective, this suggests that it is important for prescribers to involve patients in
the decision-making process when initiating or switching between formulations. Acknowledging
the limitations of a small sample sized feasibility study, which is therefore not powered to detect
statistically significant differences, a trend towards better tolerability and adherence was observed
for the liquid formulation while the tablet formulation was perceived to be more convenient by the
ambulatory participants of this study. Furthermore, persistence to the liquid at three weeks post
discharge was substantially higher than the 50% previously cited for trial participants prescribed the
tablet formulation [3]. However, this result should be interpreted with caution as persistence with the
liquid formulation was indirectly evaluated by calculating the medication possession ratio, which may
not necessarily equate to successful administration. Nonetheless, given the advantages of this positive
outcome, a definitive randomized controlled trial to establish whether this effect is maintained in a
larger more generalizable patient sample using direct measures of adherence is warranted.
The very low rate of patient refusal to complete the MAQ and try liquid alendronic acid indicates
that a future definitive study is feasible. The age and medicine regimen complexity of participants
reflects the expected population prescribed alendronic acid, affording some confidence in the likely
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generalizability of findings [22]. The good accessibility of the liquid packaging to most screened
patients contrasts previous research findings with tablet blister packaging which indicates poor
accessibility for older people [23]. Despite the participant population having approximately half the
grip strength of the average population aged over 70 years, they were all able to successfully open the
alendronic acid liquid bottle even though some had reported difficulties with popping tablets out of
blister packaging [23].
While most MAQ items demonstrated adequate to excellent internal consistency, it was weaker
for some items in the taste and convenience domains. The poor correlation in the taste domain may be
due to item ‘the medicine has no aftertaste’ not specifying whether the aftertaste was good or bad [27].
In contrast the two other items in the taste domain explicitly invite respondents to indicate whether
the formulation has a “good” taste and texture. The statement may be improved by clarifying that the
medicine has no bad aftertaste [28]. For the convenience domain, the item “is suitable to take when not
at home” correlated with fitting into lifestyle and being easy to take. The poor correlation with items
relating to dose frequency and amount may be due to the suitability of alendronic acid to take when not
at home being independent of the frequency and amount. Alendronic acid is very favorable in terms
of frequency and amount as it is a once weekly, single dose medication. However, the demanding
requirements of administration 30 min before breakfast with a glass of water is impractical when not
at home.
The largely strong positive correlations between the domain subscale and VAS scores indicate
good criterion validity. It may also be appropriate for just the domain VAS scores to be used in future
studies to evaluate patient acceptability to medicine characteristics thus reducing the questionnaire
burden from 57 items to 11 items while preserving validity. However, the poor correlation between the
tolerability subscale and VAS needs further investigation before the questionnaire can be reduced to
11 items. While the participants were reporting poor tolerability in response to the domain subscale
questions, these experiences did not translate into the overall VAS score for the tolerability domain.
This indicates that despite experiencing side effects, respondents perceived this to be acceptable.
The small sample size arising from the high rate of patient ineligibility due to not
self-administering medication, impaired cognitive function and being discharged before approach is of
concern. Recruitment in the primary care environment may provide a physically and cognitively more
able population thus overcoming the issue of recruitment prior to hospital discharge. Additionally,
duration of prior alendronic acid tablet use by participants could have been collected. This would have
enabled reporting of the duration to which the self-reported adherence relates. The present study only
reports duration of use for the liquid as the UK hospital setting does not have access to such historical
primary care prescribing data hence this was a limitation of the present study.
Order of exposure to tablet followed by liquid may account for some of the variance in the
regression model; however, given that the tablet formulation is the standard treatment for osteoporosis
in the UK, it was not feasible for an equal number of participants to be first exposed to the liquid rather
than tablet formulation.
All participants were ambulatory thus it is unsurprising that one single tablet was considered
more convenient than a 100 mL bottle of liquid given that the main driver for this preference was
the convenience of being able to take the formulation when not at home. However, all formulations
of alendronic acid are taken in the morning before food resulting in most patients administering
while at home. This reduces the likelihood of patients being able to realize the stated benefit of tablet
transportability. These findings do indicate that the restrictions of alendronic acid administration may
present a barrier to adherence and therefore should be discussed at the point of initiation [3].
The trend towards greater perceived efficacy of the tablet is interesting given the asymptomatic
nature of osteoporosis resulting in no tangible short-term effects. This perception may be due to patients
associating efficacy with experiencing tablet-associated side effects such as indigestion. Alternatively,
there may be a perceived hierarchy of medication formulation with tablets considered more effective
than liquids. The trend towards greater self-reported adherence to the liquid may be related to
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observations such as the trend towards improved tolerability with the liquid as side effects of alendronic
acid are often cited as a reason for discontinuation [2,24].
This feasibility study has provided information regarding optimal design of a subsequent study
and demonstrated the suitability of MAQ for exploring patient perceived acceptability of a medication.
It suggests that formulation characteristics should be discussed when making a prescribing decision.
The before and after nature of the study prohibits a causal link being attributed to the differences
between tablet and liquid acceptability but suggests that further research is warranted.
5. Conclusions
The MAQ is suitable for capturing patient perceived acceptability of a medication and
demonstrates reasonable psychometric properties which may be improved by further refinements.
It has discriminated between a tablet and liquid formulation providing an early indication of the
acceptability of liquid alendronic acid relative to the tablet. Medicine formulation characteristics
should be considered when making a prescribing decision.
Supplementary Materials: The Medication Acceptability Questionnaire (MAQ) is available online at https:
//www.uea.ac.uk/pharmacy/research/maq and is provided in Supplementary File S1.
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